Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Organon & Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
OGN
New York
2834
https://www.organon.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Organon & Co
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
- May 8th, 2024 12:20 am
Organon Announces Proposed $1.0 Billion Senior Notes Offering
- May 7th, 2024 11:58 am
Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
- May 5th, 2024 12:44 pm
Organon First Quarter 2024 Earnings: EPS: US$0.79 (vs US$0.70 in 1Q 2023)
- May 4th, 2024 12:43 pm
What Makes Organon (OGN) a New Buy Stock
- May 2nd, 2024 4:00 pm
Organon Reports Results for the First Quarter Ended March 31, 2024
- May 2nd, 2024 11:30 am
Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline
- Apr 25th, 2024 2:01 pm
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Apr 8th, 2024 10:15 am
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
- Apr 8th, 2024 10:00 am
On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health
- Mar 8th, 2024 2:01 pm
Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Feb 20th, 2024 1:00 pm
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Feb 15th, 2024 12:30 pm
Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
- Feb 1st, 2024 12:30 pm
Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
- Jan 10th, 2024 12:33 pm
Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
- Jan 8th, 2024 12:30 pm
Organon To Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dec 21st, 2023 12:30 pm
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines
- Dec 18th, 2023 12:30 pm
Organon To Present at the Piper Sandler 35th Annual Healthcare Conference
- Nov 21st, 2023 12:30 pm
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®
- Nov 7th, 2023 9:15 pm
Organon Reports Results for the Third Quarter Ended September 30, 2023
- Nov 2nd, 2023 11:30 am
Scroll